Tricida Investor Relations Material
Latest events
Q2 2022
Tricida
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Tricida Inc
Access all reports
Tricida Inc. is a pharmaceutical company focused on developing therapies for chronic kidney disease (CKD). The company’s lead investigational drug is designed to treat metabolic acidosis, a common complication in patients with CKD, which can lead to disease progression. Tricida aims to address unmet medical needs in the nephrology space by developing therapies that improve kidney health and patient outcomes. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
TCDA
Country
🇺🇸 United States